Gleason

Deep Bio's AI Algorithm Helps Risk Stratification for Prostate Cancer

Retrieved on: 
Thursday, May 11, 2023
ISUP, Gleason, Marie Cassidy, AUA, American Urological Association, Prognosis, Research, Johns Hopkins School of Medicine, Patient, Algorithm, Diagnosis, AI, Recurrence, Prostate cancer, Software, Medical device, Medical imaging

SEOUL, South Korea, May 11, 2023 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that Dr. Lotan from Johns Hopkins Medicine presented their collaborative research which utilized the deep learning-based algorithm for prostate cancer diagnosis support at a podium session in the American Urological Association (AUA) annual meeting 2023.

Key Points: 
  • This joint research compared human pathologists and an AI algorithm in grading prostate biopsy specimens to predict biochemical recurrence after radical prostatectomy.
  • Gleason score is one of the key elements to grade prostate cancer and can lead to different clinical decisions.
  • To compare human pathologists and AI algorithms, Deep Bio's AI-based prostate cancer diagnosis support software DeepDx® Prostate analyzed all the biopsies to provide Gleason grades as well.
  • This risk stratification has the potential to prevent a lot of unnecessary surgeries and aid in choosing between treatment modalities.

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

Retrieved on: 
Tuesday, May 2, 2023
Oncology, Health, Consumer, Genetics, Clinical Trials, Men, Biotechnology, NRG, Radiation, Prostate cancer, Gleason, Survival, University Hospitals Cleveland Medical Center, National Cancer Institute, ADT, Prognosis, National Comprehensive Cancer Network, Radiation therapy, NCCN, Journal of the National Comprehensive Cancer Network, HIV disease progression rates, Patient, Canadian International Council, Physician, Risk, SHR, Case Western Reserve University School of Medicine, Urology, RT, Biology, Metastasis, Biopsy, Medical imaging, Physics

(Nasdaq: VCYT) announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) validate the clinical utility of the company’s Decipher Prostate Genomic Classifier for helping to guide treatment selection in men with intermediate-risk prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) validate the clinical utility of the company’s Decipher Prostate Genomic Classifier for helping to guide treatment selection in men with intermediate-risk prostate cancer.
  • The findings are from NRG Oncology/RTOG 0126, a Phase 3 randomized clinical trial of patients with intermediate-risk prostate cancer treated with definitive radiotherapy without concomitant hormone therapy.
  • This is the first randomized study to validate any gene-expression biomarker in this patient population, adding further evidence to support the Decipher Prostate test’s utility.
  • Overall, men in the study with higher Decipher Prostate test scores had worse 10-year outcomes with radiotherapy (RT) alone compared to men with lower Decipher Prostate test scores.

CHUCK E. CHEESE APPOINTS SEAN GLEASON AS NEW CHIEF MARKETING OFFICER

Retrieved on: 
Monday, April 10, 2023
Advertising, University, Dr Pepper Snapple Group, Senior, Marketing, Gleason, Chuck E. Cheese, Marketing communications, Food, Pizza Hut, Dave, Cheese, Field marketing, Restaurant, Growth, Dave & Buster's, Family, CEC

IRVING, Texas, April 10, 2023 /PRNewswire/ -- CEC Entertainment, LLC., announced today the appointment of marketing veteran Sean Gleason to the position of Chief Marketing Officer for the Company's flagship brand, Chuck E. Cheese, and its virtual kitchen brands, including Pasqually's Pizza & Wings. Gleason is a marketing leader with expertise in brand development, digital media, menu innovation, and in leading high-performance teams to deliver transformational growth throughout his career.

Key Points: 
  • "I am thrilled to have Sean join CEC Entertainment to lead the marketing strategy for the world's largest family entertainment center brand, Chuck E Cheese."
  • As Chuck E. Cheese CMO, Gleason will lead all marketing functions, menu innovation, guest insights, communications, as well as the brand's digital marketing and consumer journey initiatives.
  • Gleason comes to Chuck E. Cheese with more than 25 years of marketing strategy, media, advertising, and brand experience.
  • Prior to that, Gleason led the marketing efforts at Dave & Buster's for more than a decade as Chief Marketing Officer.

Ibex's Galen™ Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR

Retrieved on: 
Thursday, February 9, 2023
Prostate, TEL, Laboratory, CE, Breast, Quality, Regulatory affairs, Diagnosis, Quality assurance, Safety, IVDR, Patient, IVDD, Pathology, Marie Cassidy, Marketing, Ibex, Gleason, Subjectivity, Journal of Diagnostic Medical Sonography, European, AI, Medical device, Medical imaging, EU

TEL AVIV, Israel, Feb. 9, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that Galen™ Prostate is now CE marked under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for supporting pathologists in primary diagnosis of prostate biopsies. Galen Prostate is the first standalone AI-based cancer diagnostics product of its kind certified under the IVDR. 

Key Points: 
  • TEL AVIV, Israel, Feb. 9, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that Galen™ Prostate is now CE marked under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for supporting pathologists in primary diagnosis of prostate biopsies.
  • Galen Prostate is the first standalone AI-based cancer diagnostics product of its kind certified under the IVDR.
  • IVDR is the new regulatory standard set by the European Union, replacing the previous In Vitro Diagnostic Medical Device Directive (IVDD).
  • Galen Prostate received its IVDR CE certificate following a rigorous review demonstrating the quality of the product and its meticulous development process, safety, and performance.

Ibex Deploys AI-powered Cancer Diagnostics Solution at UPMC

Retrieved on: 
Wednesday, December 14, 2022
Laboratory, Physician, RUO, Subjectivity, API, MD, Workflow, TEL, Diagnosis, Gleason, University of Pittsburgh Medical Center, Patient, Entrepreneurship, Cancer, Biopsy, Hospital, Deep learning, Prostate, FDA, AI, Pathology, Marie Cassidy, Artificial intelligence, University, Breast, Application, Prostate cancer, UPMC, MBA, UK, Algorithm, Medical device, Medical imaging, Ibex

TEL AVIV, Israel, Dec. 14, 2022 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the live deployment by the University of Pittsburgh Medical Center (UPMC) of Galen™ Prostate, an AI-based solution that supports pathologists during cancer diagnosis, at the UPMC network.

Key Points: 
  • TEL AVIV, Israel, Dec. 14, 2022 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the live deployment by the University of Pittsburgh Medical Center (UPMC) of Galen Prostate, an AI-based solution that supports pathologists during cancer diagnosis, at the UPMC network.
  • The Galen suite of solutions from Ibex is used in routine clinical practice at laboratories, hospitals and health systems worldwide.
  • Ibex Medical Analytics (Ibex) is transforming cancer diagnostics with world-leading, clinical grade AI-powered solutions, empowering physicians to provide accurate, timely and personalized cancer diagnosis for every patient.
  • For more information, including indication for use and regulatory approval in other countries, contact Ibex Medical Analytics.

Deep Bio and Visiopharm Announce a Collaborative Integration of a Clinical-Grade AI Prostate Cancer Solution with a Leading Digital Pathology Platform

Retrieved on: 
Tuesday, November 15, 2022
Health, Medicine, Digital, Technology, Pathology, Prognosis, Marie Cassidy, LIMS, Prostate, Gleason, Deep learning, Partnership, Software, Efficiency, Cancer, Medical device, Time, IVD, Intelligence, Research, APP, SSM-700K Haeseong, Prostate cancer, Breast, CEO, Workload, PACS, Hospital, H&E, Diagnosis, AI, Drug development, Solution, Medical imaging, Medicon Valley

SEOUL, South Korea, Nov. 15, 2022 /PRNewswire-PRWeb/ -- Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the latest AI-powered prostate cancer solution.

Key Points: 
  • Deep Bio's deep learning-based CE-IVDD prostate cancer diagnosis support software, DeepDx Prostate, empowers pathologists by identifying cancerous areas and grading their severity providing a Gleason scoring.
  • With its extensive AI-based image analysis solutions for multiple cancer types, Visiopharm's platform is contributing to the global adoption of digital pathology and AI.
  • The two companies plan to add additional AI cancer pathology solutions over time for prostate and breast, among others.
  • Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology.

Ibex Announces Galen™ 3.0 Cancer Diagnostics Platform

Retrieved on: 
Sunday, September 4, 2022
Breast, Deep, Technology, Cancer, Research, Application, Deep learning, Squamous cell carcinoma, Artificial intelligence, Pathology, Solution, Gleason, Subjectivity, Physician, Product management, Marie Cassidy, LinkedIn, API, Diagnosis, Neuroendocrine tumor, Laboratory, Hospital, Version 3.0 (album), Lymphoma, TEL, Twitter, Algorithm, European Congress of Radiology, Prostate, Carcinoma in situ, Report, Review, AI, Medical imaging, Ibex

TEL AVIV, Israel, Sept. 4, 2022 /PRNewswire/ -- Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, today announced the launch and roll-out of Galen™ 3.0, a transformative solution offering new detection capabilities and a broad set of features to support pathologists in the diagnosis of multiple tissue types across various digital pathology workflows. Galen 3.0 is CE-Marked, approved in additional countries and now generally available to Ibex customers.  

Key Points: 
  • Galen 3.0 is CE-Marked, approved in additional countries and now generally available to Ibex customers.
  • Galen 3.0 incorporates the very latest evolution of Ibex's AI algorithms for detecting cancer and other clinically relevant features in prostate, breast, and gastric biopsies.
  • Galen also calculates a Gleason score, tumor size and percentage for each cancer slide, potentially enabling pathologists to save review time and reduce subjectivity.
  • Ibex is transforming cancer diagnostics with world-leading, clinical grade AI-powered solutions, empowering physicians to provide accurate, timely and personalized cancer diagnosis for every patient.

Deep Bio successfully integrates DeepDx® Prostate algorithm into HALO AP® platform from Indica Labs

Retrieved on: 
Tuesday, August 9, 2022
Multimedia, Medicine, Prostate cancer, Sun-woo Kim, CEO, Algorithm, Diagnosis, AI, Cancer, Software, HALO, Prognosis, View, Marie Cassidy, Partnership, Deep learning, AP, SDK, IVD, Workflow, Pathology, Medical device, Prostate, Oncology, Gleason, Efficiency, Norwich Pharma Services, Medical imaging

HALO AP incorporates state-of-the-art workflow management tools allowing users to easily integrate quantitative analytics and AI tools built using HALO, HALO AI and third-party algorithms, such as DeepDx.

Key Points: 
  • HALO AP incorporates state-of-the-art workflow management tools allowing users to easily integrate quantitative analytics and AI tools built using HALO, HALO AI and third-party algorithms, such as DeepDx.
  • To simplify integration, a HALO AP analysis software development kit (SDK) including sample code is available to all algorithm developers.
  • DeepDx Prostate analysis can be triggered directly in HALO AP by selecting the DeepDx workflow or run automatically via the HALO AP API.
  • To learn more about analyzing prostate cores with DeepDx Prostate in HALO AP, contact Deep Bio at [email protected] for a full demonstration.

Indica Labs achieves CE-IVD certification for AI-based Prostate Cancer Detection and Gleason Grading Tool

Retrieved on: 
Monday, May 23, 2022
Hamamatsu, University of Cologne, Patient, Health, Prostate, Solution, Algorithm, Efficiency, Prostate cancer, Grade (bouldering), Pressure, LIS, Man, Gleason, Neoplasm, Hospital, Kappa, Workload, Pathology, University, AP, Digital, PSA, Cancer, Marie Cassidy, HALO, Norwich Pharma Services, Medical imaging

Prostate cancer is the most common cancer diagnosed in men.

Key Points: 
  • Prostate cancer is the most common cancer diagnosed in men.
  • HALO Prostate AIis designed to work alongside the pathologist to improve efficiency and to add a layer of quality control to ensure diagnostic accuracy.
  • HALO Prostate AI showed very high accuracy in the large multi-institutional study for tumor detection and Gleason Grading in prostate biopsies.
  • HALO Prostate AIis deployed through Indica Labs' CE-IVD marked HALO AP platform to provide a fully validated and automated end-to-end workflow.

Deep Bio Wins Approval for World's First AI-based Prostate Cancer Severity Grading Software from Korea MFDS

Retrieved on: 
Wednesday, November 24, 2021
CTO, Algorithm, CEO, Prostate cancer, Technology, Deep learning, AI, Diagnosis, Korean, IVD, Ministry of Food and Drug Safety, Gleason, MFDS, Kappa, Breast cancer, Ministry, Biopsy, Prognosis, Haematoxylin, Software, Medicine, TURP, Prostatectomy, Bladder cancer, III, Medical device, Marie Cassidy, Classification, Sun-woo Kim, Pathology, Medical imaging

This milestone is Deep Bio's second Korean MFDS regulatory approval, following the clearance of a model for prostate cancer detection last year.

Key Points: 
  • This milestone is Deep Bio's second Korean MFDS regulatory approval, following the clearance of a model for prostate cancer detection last year.
  • DeepDx-Prostate Pro analyzes WSIs (Whole Slide Images) of H&E (Hematoxylin & Eosin) stained prostate core needle biopsies and automatically classifies the histological severity of prostate cancer.
  • "It is deeply meaningful that Deep Bio introduces the world's first clearance of AI technology that aids grading the severity of prostate cancer in pathological tissue diagnosis," stated Sun Woo Kim, the CEO of Deep Bio.
  • Tae Yeoung Kwak, the CTO of Deep Bio said "Deep Bio's AI technology for analyzing prostate cancer has gained a global reputation following presentation in international conferences and academic journals.